FDA Clears First AI Tool Designed to Catch Hidden Heart Attacks on ECG
An AI-powered ECG model just received FDA De Novo authorization for detecting heart attacks standard reads routinely miss, potentially saving lives.
Summary
The FDA has granted De Novo authorization to Queen of Hearts, an AI-powered ECG tool developed by Powerful Medical, making it the first of its kind cleared specifically to detect acute heart attacks — including hard-to-spot STEMI equivalents that standard clinical readings frequently miss. Built into the PMcardio platform, the tool works at the earliest points of patient contact, from ambulances to emergency rooms, flagging dangerous heart patterns before a cardiologist is even in the room. Data from more than 20 peer-reviewed studies covering over 40,000 patients show the AI catches roughly twice as many true heart attacks as standard interpretation while cutting false positives by up to fivefold. In Europe, where it already holds CE-marking, the tool flagged more than 120,000 heart attacks in 2025 alone.
Detailed Summary
Heart disease remains the world's leading cause of death, and speed of diagnosis is often the decisive factor in how much damage a heart attack inflicts — or whether a patient survives at all. Yet the humble ECG, medicine's front-line cardiac tool, routinely misses a meaningful proportion of acute heart attacks, especially STEMI equivalents, patterns indicating arterial blockage that don't display the textbook signs physicians are trained to recognize quickly.
Powerful Medical's Queen of Hearts AI model was built to close that gap. On September 4, the company announced FDA De Novo authorization — the agency's pathway for genuinely novel devices — making it the first AI ECG tool ever cleared specifically for acute heart attack detection. The system integrates into the PMcardio platform and runs at the first point of medical contact, whether that's a paramedic in an ambulance or an ER nurse, accelerating hand-off to cardiology.
The evidence base is substantial. More than 20 peer-reviewed studies, including randomized controlled trials published in major cardiovascular journals and spanning over 40,000 patients across four continents, underpin the authorization. The pooled data show Queen of Hearts detects roughly twice as many true heart attacks as standard-of-care ECG interpretation and reduces false positives by as much as fivefold — a combination that both speeds treatment and reduces unnecessary interventions.
Real-world performance in Europe backs the trial data. Following CE-marking, the tool identified more than 120,000 heart attacks in 2025, and in over half of those cases helped accelerate time-to-treatment — the metric most directly tied to myocardial muscle survival.
For longevity-focused readers, the relevance extends well beyond acute care. Surviving a heart attack with less cardiac damage preserves heart function, which is tightly coupled to long-term healthspan, physical capacity, and all-cause mortality risk. Tools that reduce permanent cardiac injury effectively protect the organ most responsible for sustaining physical capability into later life.
Key Findings
- Queen of Hearts is the first FDA-authorized AI ECG tool specifically designed to detect acute heart attacks, including STEMI equivalents.
- The AI detects roughly twice as many true heart attacks as standard ECG interpretation across 40,000+ patients in peer-reviewed trials.
- False positives were reduced by up to fivefold compared to standard clinical ECG reads, cutting unnecessary interventions.
- In Europe, the tool identified over 120,000 heart attacks in 2025 and sped up treatment in more than half of those cases.
- Faster diagnosis preserves heart muscle, directly protecting long-term cardiac function and physical healthspan.
Methodology
This is a news report covering a regulatory milestone and company announcement, not a primary research paper. Evidence cited includes 20+ peer-reviewed studies and randomized controlled trials across 40,000+ patients, published in major cardiovascular journals — a credible and substantial evidence base. Independent verification of the underlying trial data is advised before drawing clinical conclusions.
Study Limitations
The article relies heavily on company-issued statements and press release data; independent audit of the 20+ cited studies is needed to confirm effect sizes. Long-term outcomes data on patient survival and cardiac function post-detection are not reported. Real-world US performance may differ from European deployment results due to differences in clinical workflow and patient populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: